請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

TAL Education Group Files Its Annual Report on Form 20-F

PR Newswire (美通社)

更新於 2025年06月16日20:59 • 發布於 2025年06月16日20:25 • PR Newswire

BEIJING, June 17, 2025 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE: TAL), a smart learning solutions provider in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended February 28, 2025 (the "Annual Report") with the Securities and Exchange Commission (the "SEC") on June 16, 2025, U.S. Eastern Time.

The Annual Report can be accessed and downloaded on the Company's website at , as well as on the SEC's website at .

Shareholders and ADS holders of the Company may request a hard copy of the Annual Report free of charge by emailing the Company at or by writing to the following address:

TAL Building No.1 Courtyard No.9
Qixin Middle Street, Changping District
Beijing 102200
People's Republic of China
Attention: Jackson Ding

About TAL Education Group

TAL Education Group is a smart learning solutions provider in China. The acronym "TAL" stands for "Tomorrow Advancing Life", which reflects our vision to promote top learning opportunities for students through both high-quality teaching and content, as well as leading edge application of technology in the education experience. TAL Education Group offers comprehensive learning solutions to students from all ages through diversified class formats. Our learning solutions mainly cover enrichment learnings programs and some academic subjects in and out of China. Our ADSs trade on the New York Stock Exchange under the symbol "TAL".

For investor and media inquiries, please contact:

In China:

Jackson Ding
Investor Relations
TAL Education Group
Tel: +86 10 5292 6669-8809
Email:

Piacente Financial Communications
Helen Wu
Tel: +86-10-6508-0677
Email:

In the United States:

Piacente Financial Communications
Brandi Piacente
Phone: +1-212-481-2050
Email:

查看原始文章

Mibro Unveils Three New Smartwatches, Highlighting Sports-Tech Innovation and Brand Transformation

PR Newswire (美通社)

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

PR Newswire (美通社)

CCTV-4's Special Central Asia Season

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...